Novel Drug May Help Adults with Obesity Lose Up to 22.5% Weight
CT-388, a dual GLP-1/GIP agonist, demonstrated over 22% weight loss at 48 weeks, offering a promising new treatment option for adults with obesity.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.